Contract awarded for biodetection system

Northrop Grumman’s BioWatch Gen-3 program, a new generation of autonomous biodetection instruments, was recently awarded a new contract by the U.S. Department of Homeland Security.

The $8.4 million contract was granted under the BioWatch Gen-3 System Performance Demonstration Contract. This original contract is potentially worth $37 million over the span of three years.

Under the terms of the new contract, Northrop Grumman will test 12 of the detection units in both indoor and outdoor environments in a major city in the United States in order to determine their readiness to be deployed. The company intends to provide both the detection equipment and the technical support needed to get the systems fully operational.

"The NG-ADS technology has the potential to significantly improve the nation's ability to quickly detect and respond to a bioterrorism event," Dave Tilles said. Tilles is the director of Homeland Security and CBRNE defense programs for the Advanced Concepts & Technologies Division at Northrop Grumman's Electronic Systems sector.

"This effort builds on the company's work to support our customers as they enhance the country's defenses against potentially catastrophic threats such as bioterrorism," Tilles said.

The BioWatch Gen-3 program detectors operate all day every day. DHS envisions the system to be fully autonomous and capable of continually monitoring the air in major population centers.